Smoking Cessation Program

About Qnovia

Qnovia, founded in 2019 and based in Richmond, USA, is a private, pre-revenue biotech company developing a disruptive inhaled drug delivery platform. The company's core technology is positioned as a versatile platform capable of delivering various drugs, with its lead application targeting smoking cessation, for which it has an active IND and is pursuing FDA and MHRA approvals. Led by founder and CEO Mario Danek and supported by a team with deep regulatory and commercial experience, including former FDA Center for Tobacco Products director Mitch Zeller, Qnovia aims to partner with larger healthcare companies to bring its technology to market.

Therapeutic Areas

Other Smoking Cessation Drugs